David M. Vail
Department of Medical Sciences
- Residency in Medical Oncology, Colorado State University
- M.S. in Comparative Oncology, Colorado State University
- D.V.M., University of Sasckatchewan
B.Sc. in Pathogenic Microbiology, University of Alberta
Dr. Vail's research involves the design and implementation of comparative oncology clinical trials through the inclusion of companion animal dogs and cats with spontaneous tumors. These spontaneous tumors have similar biological behavior as their counterparts in humans. The information obtained from these clinical trials help inform both the design of future trials in humans as well as provide preliminary data on ongoing drug development programs for animal health. Dr. Vail has published over 120 peer-reviewed scientific manuscripts and 50 book chapters in the field of veterinary and comparative oncology. David is co-editor of the textbook Small Animal Clinical Oncology, past North American Journal Editor for Veterinary and Comparative Oncology, President of the Canine Comparative Oncology and Genomics Consortium (CCOGC) and a founding member of the Comparative Oncology Trials Consortium (COTC). He is the past Chairman of the Scientific Advisory Boards for both the Morris Animal Foundation and the American College of Veterinary Internal Medicine Foundation. He has been honored as the recipient of both the Mark L. Morris Sr. Distinguished Research Award and the Pfizer Award for Veterinary Research Excellence.
- Professor of Oncology
- Barbara A. Suran Chair in Comparative Oncology
- Director of the Barbara A. Suran Comparative Oncology Research Institute
Vail DM, von Euler H, et al. A randomized trial investigating the efficacy and safety of water soluble paclitaxel (Paccal® Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. J Vet Intern Med. 2012 Mar 6. doi: 10.1111/j.1939-1676.2012.00897.x. [Epub ahead of print].
Vail DM, Husbands BD, Kamerling SG, et al. Phase I study to determine the maximum tolerated dose and dose-limiting toxicities of oral idarubicin in dogs with lymphoma. J Vet Intern Med. 2012 Mar 9. doi: 10.1111/j.1939-1676.2012.00896.x. [Epub ahead of print].
Chon E, McCartan L, Kubicek LN, Vail DM. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumor-bearing dogs (excluding mast cell tumors): a Phase I dose-finding study. Vet Comp Oncol. 2011 Mar 21. doi: 10.1111/j.1476-5829.2011.00265.x. [Epub ahead of print].
Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I, Vail DM. Safety Evaluation of Combination Vinblastine and Toceranib Phosphate (Palladia®) in Dogs: a Phase I dose-finding study. Vet Comp Oncol. 2011 Jan 31. doi: 10.1111/j.1476-5829.2011.00261.x. [Epub ahead of print].
Vail DM, Michels GM, Khanna C, Selting KA, London CS, and the Veterinary Co-operative Oncology Group. Response Evaluation Criteria For Peripheral Nodal Lymphoma in Dogs (v1.0) - A Veterinary Co-operative Oncology Group (VCOG) Consensus Document. Vet Comp Oncol 8(1):28-37, 2010.
Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ, Kraft SL, Gustafson DL, Vail DM. Preclinical Investigation of PEGylated Tumor Necrosis Factor Alpha in Dogs with Spontaneous Tumors: Phase I Evaluation. Clin Cancer Res 16(5):1498-508, 2010.
Lawrence J, Vanderhoek M, Barbee D. Jeraj R, Tumas DB, Vail DM. Use of 3’-deox 3’-[18F]Fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin’s lymphoma. Vet Rad Ultrasound 50(6):660-668, 2009.
Vail DM, Thamm DH, Tumas DB, Reiser H, Ray AS, Wolfgang GHI, Babusis D, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J. Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma. Clin Cancer Res 15:3503-3510, 2009.
Turek MM, D. H. Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR, Vail DM. hGM-CSF DNA Cationic-lipid complexed autologous tumor cell vaccination in the treatment of canine b-cell multicentric lymphoma. Vet Comp Oncol 5(4):219-231, 2007.
Alexander AN, Huelsmeyer MK, Mitzey M, Dubielzig RR, Kurzman ID, MacEwen EG, Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a Phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 55:433-442, 2006.